Direct RT-PCR Norovirus Detection Without Nucleic Acid Extraction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting Norovirus genogroups I and II in stool samples are inefficient due to the need for nucleic acid extraction and purification, which can lead to degradation and require preservatives or freezing, limiting rapid and accurate detection.
Innovation Solution
A method involving direct amplification of Norovirus genogroup-specific target nucleic acids in stool samples using primer pairs and real-time RT-PCR without prior extraction, allowing for simultaneous detection of Norovirus genogroup I and II using fluorescently labeled probes in a streamlined process.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If nucleic acid extraction and purification are performed on stool samples, then detection accuracy is improved, but processing time and complexity increase
Solution Approach 1:
The patent eliminates the nucleic acid extraction step from the detection workflow. The direct RT-PCR method allows viral nucleic acid to be amplified directly from stool samples without requiring extraction and purification, thereby reducing processing time while maintaining detection accuracy through optimized primer and probe designs that specifically target norovirus sequences in complex stool matrices.
Solution Approach 2:
The patent employs separate primer and probe sets for different norovirus genogroups (GI and GII), allowing simultaneous detection of multiple virus types in a single assay. This segmentation of detection targets enables accurate discrimination between different norovirus strains without requiring separate extraction procedures for each genotype.
2Measurement precision
If nucleic acid extraction is performed, then detection sensitivity is improved, but sample degradation occurs and preservatives or freezing are required
Solution Approach 1:
The direct RT-PCR system is designed to function directly in the complex stool sample matrix without requiring nucleic acid extraction. The assay components (primers, probes, and enzymes) are formulated to tolerate inhibitors present in stool samples, allowing the system to serve itself by performing detection in the native sample environment without additional processing steps that could cause degradation.
Solution Approach 2:
The patent optimizes the chemical parameters of the RT-PCR reaction conditions to enable direct amplification from stool samples. By adjusting buffer composition, enzyme concentrations, and cycling parameters, the system achieves sufficient sensitivity and specificity without extraction, thereby maintaining nucleic acid stability and eliminating the need for preservatives or freezing during processing.
3Adaptability or versatility
If multiple Norovirus genogroups are detected simultaneously, then diagnostic comprehensiveness is improved, but assay complexity increases
Solution Approach 1:
The patent creates a universal detection platform that can simultaneously identify multiple norovirus genogroups (GI and GII) using a single RT-PCR assay. The system employs multiple primer and probe sets that are all activated in one reaction mixture, allowing the assay to perform multiple detection functions simultaneously without requiring separate tests for each genotype, thereby reducing overall assay complexity while expanding detection scope.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables rapid, sensitive, and simultaneous detection of Norovirus genogroups I and II in stool samples without extraction, improving diagnostic accuracy and reducing sample processing time and complexity.
Implementation Method 1
simultaneous detection of Norovirus genogroup I and II using fluorescently labeled probes in a streamlined process
Data Source
AI summary
The present disclosure provides methods and compositions for determining whether a patient exhibiting acute gastroenteritis will benefit from treatment with therapeutic agents that inhibit Norovirus genogroup I (GI) or Norovirus genogroup II (GII). The methods disclosed herein are based on detecting Norovirus genogroup I (GI) and Norovirus genogroup II (GII) in a stool sample without extracting viral nucleic acids from a clinical specimen prior to performing real-time reverse transcription PCR. Kits for use in practicing the methods are also provided.